DexCom, Inc.’s Stelo continuous glucose monitor (CGM) became available in the US on 26 August for diabetics, prediabetics and healthy consumers alike, making it the first such product sold in the country that does not require a prescription.
Dexcom’s Stelo Continuous Glucose Monitor Now Available OTC In US
Dexcom announced the launch of Stelo, the first non-prescription continuous glucose monitoring system to hit the US market, but is likely going to face competition soon from Abbott.
More from Business
• By
HBW Insight speaks to AESGP director general Jurate Švarcaite about what's on the agenda for the upcoming 61st AESGP Annual Meeting, which will take place in Warsaw, Poland, between 2-4 June. Highlights include the role of prevention in self-care, discussions about how regulators will ensure the competitiveness of European industry on the world stage and incoming changes to sustainability legislation.
• By
A round-up of the latest consumer health industry appointments: GSCF elects chair; Kenvue hires Northern Europe head; Barentz names chief commercial officer.
• By
Galenica outpaced the growth of the OTC market at home, while recording a double-digit gain abroad, to drive up its consumer health product sales in 2024.
• By
Alliance shareholders overwhelmingly back takeover by DBAY Advisors after improved offer values UK-based firm at £362m.
More from Beauty
• By
Cosmetic companies should conduct audits to identify products that will be required to disclose fragrance allergens and begin the work of adjusting labels, particularly for smaller packaging, says a director at Registrar Corp., during a 12 March webinar on MoCRA and labeling.
• By
Cosmetics companies brace for the impact of Trump administration tariffs as industry experts seeing an opportunity for an exemption urge stakeholders to reach out to lawmakers. The issue was discussed during PCPC’s recent Beauty Collective Summit.
• By
RoC launches RoC 35 Protocol, a five-product regimen backed by the brand’s largest clinical assessment yet, showing 200 subjects saw significant improvement in ‘key parameters’ of skin aging.